点击下载:国产JAK抑制剂迎来新进展,多款在研产品积极推进中{国产JAK抑制剂迎来新进展,...查看全文
药智网2022-12-05 15:06
脱发星人的「治疗指南」
来源:药智网/费翔
“天下苦脱发久矣。”
尚没有一副铮铮铁骨,能经得住这个四两拨千斤的拷问:你敢直面秃头么?
据世卫组织统计,全世界约有16亿人因脱发而遭受折磨。截至2021年底,我国脱发人口约为2.67亿人,到2026年底,这一数字将进一步提高到...查看全文
药明在线2022-11-25 16:34
近日,Concert Pharmaceuticals公布了其研究性口服药物deuruxolitinib(CTP-543)在中度至重度斑秃成年患者中的3期临床试验中更新的数据。据新闻稿,deuruxolitinib对脱发最严重以及脱发持续时间较长的患者也有显著的改善。
斑秃是一种自身免疫性疾病,免疫系统攻击毛囊,导致头皮和身体上的毛...查看全文
柚子阿泰02-29 14:19
What’s innate is that humans use concepts to build social reality, and social reality, in turn, wires the brain. Emotions are very real creations of social reality, made possible by human brains in concert with other human brains.查看全文
DeepTech深科技2022-05-26 21:55
5 月 23 日,位于马萨诸塞州的临床阶段生物公司 Concert Pharmaceuticals(NASDAQ:CNCE,以下简称 “Concert”)宣布了其最新的 3 期临床试验 THRIVE-AA1(NCT04518995)阳性顶线结果,该试验评估了其口服药物 CTP-543 对于成人中度至重度斑秃的治疗结果。
据悉,Concert 共围绕 CTP-543 开...查看全文
医药魔方2022-05-25 20:25
5月23日,Concert Pharmaceuticals公司宣布,其口服JAK抑制剂CTP-543针对中重度斑秃成年患者的III期临床(THRIVE-AA1)达到了主要研究终点和关键次要终点。结果显示,与安慰剂相比,在治疗24周后,高剂量组(12mg)有41.5%的患者实现头皮毛发覆盖率至少80%。
THRIVE-AA1是一项随机双盲、安慰剂...查看全文
SeekingBiotech2022-05-24 23:08
氘代的JAK新药 CTP-543 ,斑秃3期临床试验成功。
Deuterated Derivatives Of Ruxolitinib...
一D解千愁么。$Concert(CNCE)$查看全文
药时代2022-05-25 13:16
周一上午,Concert Pharmaceuticals公布了其最新的III期临床试验THRIVE-AA1(NCT04518995)阳性顶线结果,表明主要终点和所有“关键的次要终点”都达到了要求。
两个月前,Concert Pharmaceuticals将其大部分中枢神经系统(CNS)管线出售给了Terran Biosciences。
投资者对这一消息感到高...查看全文
$Concert(CNCE)$ 15-12G Securities registration termination [Section 12(g)] Accession Number: 0000950103-23-004201 Act: 34 Size: 12 KB 网页链接
$Concert(CNCE)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-000562 Act: 33 Size: 1 KB 网页链接
$Concert(CNCE)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-000557 Act: 33 Size: 1 KB 网页链接
$Concert(CNCE)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-000566 Act: 33 Size: 1 KB 网页链接
$Concert(CNCE)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-000559 Act: 33 Size: 1 KB 网页链接
$Concert(CNCE)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001354457-23-000156 Act: 34 Size: 3 KB 网页链接
$Concert(CNCE)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-061025 Act: 33 Size: 28 KB 网页链接
$Concert(CNCE)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-061029 Act: 33 Size: 28 KB 网页链接
$Concert(CNCE)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-061014 Act: 33 Size: 28 KB 网页链接
$Concert(CNCE)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-061021 Act: 33 Size: 28 KB 网页链接